Source: Annals of oncology. Conference titles: 42nd European-Society-for-Medical-Oncology Congress (ESMO). Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, PROGNÓSTICO, SOBREVIVÊNCIA LIVRE DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BACHELOT, T et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://observatorio.fm.usp.br/handle/OPI/25260. Acesso em: 06 nov. 2024. , 2017APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://observatorio.fm.usp.br/handle/OPI/25260NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2024 nov. 06 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [Internet]. Annals of oncology. 2017 ; 28[citado 2024 nov. 06 ] Available from: http://observatorio.fm.usp.br/handle/OPI/25260
